PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Economics, Pharmaceutical”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed2026

Meta-analysis and pharmacoeconomic study of rasagiline versus selegiline in the treatment of Parkinson's disease.

OBJECTIVE: Given the persistent absence of direct head-to-head trials, this study aimed to evaluate the comparative efficacy, safety, and cost-effectiveness of rasagiline versus selegiline as early-stage monotherapy for Parkinson's disease (PD), informing clinical selection and healthcare policies in China. METHODS: A systematic search of PubMed, Embase, and the Cochrane Library identified randomized controlled trials (RCTs) up to April 2026. Focusing on short-term outcomes (10-16 weeks), an adjusted indirect treatment comparison (ITC) using placebo as a common anchor evaluated symptom improvement (UPDRS total scores) and adverse event (AE) incidence. For economic evaluation, a 2-year Markov model was constructed from a Chinese healthcare-system perspective. The incremental cost-effectiveness ratio (ICER) was calculated alongside robust sensitivity analyses. RESULTS: Ten RCTs (rasagiline: 6; selegiline: 4) were included. The ITC revealed no statistically significant differences between rasagiline and selegiline in short-term symptomatic relief (Mean Difference = -0.82, 95% CI [-2.08, 0.44], p = 0.203) or AE risk (Odds Ratio = 0.83, 95% CI [0.50, 1.38], p = 0.475). The overall evidence certainty was rated as moderate. Economically, the base-case simulation indicated rasagiline yielded a marginal benefit of 0.0088 QALYs over selegiline but incurred an additional 17,111.10 Yuan. This resulted in an ICER of 1,951,505.55 Yuan/QALY, substantially exceeding the conventional willingness-to-pay threshold. CONCLUSION: Supported by moderate-certainty evidence, rasagiline and selegiline provide comparable short-term efficacy and safety for early-stage PD monotherapy. However, at its current pricing, rasagiline is not cost-effective. Significant price reductions or definitive proof of long-term superiority are required to justify its economic value.

Humans↗
PubMed1977

Comprehensive pharmaceutical services in an 85-bed hospital: a one-year evaluation.

The economics of a comprehensive pharmaceutical service in a small hospital was evaluated. The pharmacy program includes total unit dose drug distribution, centralized compounding of intravenous admixtures, and clinical involvement. Data were collected for two fiscal years prior to the development of formal pharmaceutical services (FY 72-73 and FY 73-74), the fiscal year during the implementation phase (FY 74-75) and the fiscal year following full development (FY 75-76). The total cost of the pharmaceutical services for FY 75-76 was $5.66 per patient day, a 106% increase over the previous year. The revenue per patient day in FY 75-76 was $7.77, a 72% increase over FY 74-75. Inventory costs decreased during and after implementation of comprehensive pharmaceutical services. The evaluation emphasizes the need for assessing pharmacy programs as an integrated system representative of the service of pharmacy. The need for an equitable method of third party payment for pharmaceutical services is discussed.

Costs and Cost Analysis↗
PubMed1978

Harvey A. K. Whitney Lecture: Patient accountability--pharmacists' future.

A philosophy of pharmacy practice is expressed, centering on service and accountability to the patient. To attain the goal of comprehensive pharmaceutical services, one must consider the factors of the environment and the characteristics of individual pharmacists. Aspects of the environment include support by the hospital administration and medical staff, and team cooperation among pharmacists and among all health professionals. Individual motivation to perform must be based on service to the patient. It is suggested that economic justification of pharmaceutical services should be a major goal of pharmacy organizations. The problem of employment opportunities for young pharmacists is discussed. The future of pharmacy practice is bright if pharmacists center their activity around the patient and become accountable for patient services.

Attitude of Health Personnel↗
PubMed1978

Market structure and advertising in the U.S. pharmaceutical industry: some implications for public policy.

Distortions in market processes for pharmaceuticals raise the important policy problem of devising measures to improve industry performance. This paper first reviews the basic issues involved in formulating economic policy regarding the pharmaceutical industry. Methods for reducing structural market power and undesirable promotional expenditures are examined, and the impacts of four oft-suggested policy "reforms"--removal of trade names, removal of patents, relaxation of requirements for certification of new drug products, and increased enforcement of antitrust laws--are then analyzed. Finally, problems requiring additional research are identified.

Advertising↗
PubMed1976

The utility of pharmacokinetics to the pharmaceutical industry.

Pharmacokinetic studies done early in the course of drug development can favorably influence the course of research by suggesting optimum dosage regimens, drug delivery methods, and fixed-ratio combinations and by alerting the clinical pharmacologist to potential problems. Pharmacokinetic data can be useful in the design of rational clinical drug research and thereby expedite clinical trials and save research costs. Thus, in addition to their value in the area of comparative bio-availability, pharmacokinetic studies carried out by the pharmaceutical industry are useful economically as well as scientifically.

Animals↗
PubMed1978

The pharmaceutical industry: a further study in corporate power.

This article represents an updated version of previous research conducted on the United States pharmaceutical industry. The unstated purpose of this article is to present new findings which supplement the earlier research. This article describes three aspects of the United States pharmaceutical industry: its strategy and structure within the world market, its global expansion beyond the territorial boundaries of the United States, and its interlocking directorates with banking institutions. The thesis presented here is twofold: first, the United States pharmaceutical industry has become increasingly integrated into larger and more heterogeneous production units operating on the world market; and second, the United States pharmaceutical industry has become increasingly linked to large United States banking firms through interlocking directorates.

Drug Industry↗